Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 5/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.47 |
| ▸ | RAF1 | P04049 | 3/20 | 0.41 |
| ▸ | BRAF | P15056 | 3/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247195 | 0.94 | PIK3CD (0.64) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL247845 | 0.93 | PIK3CD (0.66) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL247989 | 0.92 | PIK3CD (0.68) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL249076 | 0.92 | PIK3CD (0.64) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL247664 | 0.91 | PIK3CD (0.58) | PIK3CDPIK3CARAF1BRAFPIK3CB | |
| SCHEMBL248015 | 0.91 | PIK3CD (0.63) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL248764 | 0.91 | PIK3CD (0.60) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL252021 | 0.91 | PIK3CD (0.68) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL247696 | 0.90 | PIK3CD (0.60) | PIK3CDPIK3CARAF1BRAFPIK3CB | |
| SCHEMBL246384 | 0.90 | PIK3CD (0.65) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PIK3CD 24/4885PIK3CA 28/4885RAF1 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.